BSD Reports Successful Promotion of the MicroThermX® Microwave Ablation System at CIRSE by Terumo Europe (NV)

  BSD Reports Successful Promotion of the MicroThermX® Microwave Ablation
  System at CIRSE by Terumo Europe (NV)

  *Terumo showcases MicroThermX at world's largest interventional radiology
    conference
  *MicroThermX featured on Terumo’s Interventional Oncology Solutions website
  *Physician interest in the MicroThermX exceeded our expectations

Business Wire

SALT LAKE CITY -- October 9, 2013

BSD Medical Corporation (NASDAQ: BSDM) (“Company” or “BSD”), today reported
the successful promotion of the MicroThermX® Microwave Ablation System
(MicroThermX) at the Cardiovascular and Interventional Radiological Society of
Europe (CIRSE) conference in Barcelona, Spain. Terumo Europe NV (Terumo), a
wholly owned subsidiary of Terumo Corporation, used CIRSE as the main
launching pad to showcase BSD's MicroThermX as an integral part of its branded
Interventional Oncology Solutions (IOS). CIRSE is the world's largest and most
prestigious conference in the field of minimally invasive image-guided
therapies.

Hundreds of physicians attended the MicroThermX symposium, including key
physician opinion leaders throughout Europe. Terumo, the leader in
interventional oncology, now features MicroThermX as one of the key products
in its interventional oncology portfolio:
http://www.terumo-europe.com/endovascular/interventional-oncology-solutions/.

“We see tremendous opportunity for fast adoption in Europe for our MicroThermX
Microwave Ablation System because the structure of the healthcare systems in
the area is focused on cost-effective solutions and faster adoption of new
superior technology,” said Harold Wolcott, BSD President and CEO. “The
physician response and interest in the MicroThermX far exceeded our
expectations. We are very pleased with our relationship with Terumo.”

About Terumo Corporation

A world leader in state-of-the-art medical devices and interventional
oncology, Tokyo-based Terumo Corporation (TYO: JP:4543) reported 2013 sales of
nearly $5 billion and has a market cap in excess of $8 billion. Through the
sale and promotion of a high quality line of devices used for tumor
embolization, the closing or blocking of blood vessels, Terumo Europe NV has
established itself as a pioneer in the field of interventional oncology.

About the MicroThermX^® Microwave Ablation System

The MicroThermX is a compact, mobile, state-of-the-art, proprietary system
that includes a microwave generator, single-patient-use disposable antennas,
and a thermistor-based temperature monitoring system. The innovative design of
the MicroThermX is the first of its kind that allows delivery of higher power
levels using a single generator. The MicroThermX utilizes innovative
synchronous phased array technology that was developed and patented by BSD to
provide a wide range of uniform zones of ablation. The MicroThermX includes
innovative, high-end disposables (SynchroWave antennas) that are used in each
ablation treatment and will provide a significant ongoing revenue stream. The
soft tissue (tumor) ablation world market potential is estimated to exceed
$2.3 billion. The U.S. Food and Drug Administration (FDA) has granted the
Company a 510(k) clearance to market the MicroThermX for ablation of soft
tissue. BSD has also received CE Marking for the MicroThermX System, which
allows BSD to market the MicroThermX in Europe. CE Marking is also recognized
in many countries outside of the EU, providing BSD the ability to market the
MicroThermX to a number of international markets.

About BSD Medical Corporation

BSD Medical Corporation develops, manufactures, markets and services systems
to treat cancer and benign diseases using heat therapy delivered using focused
radiofrequency (RF) and microwave energy. BSD’s product lines include both
hyperthermia and ablation treatment systems. BSD’s hyperthermia cancer
treatment systems, which have been in use for several years in the United
States, Europe and Asia, are used to treat certain tumors with heat
(hyperthermia) while increasing the effectiveness of other therapies such as
radiation therapy. BSD’s microwave ablation system has been developed as a
stand-alone therapy to employ precision-guided microwave energy to ablate
(destroy) soft tissue. The Company has developed extensive intellectual
property, multiple products in the market and established distribution in the
United States, Europe and Asia. Certain of the Company’s products have
received regulatory approvals and clearances in the United States, Europe and
China. For further information visit BSD Medical's website at
www.BSDMedical.com.

This press release may be deemed to contain forward-looking statements, which
are subject to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995, including the expected use of proceeds relating to the
recently completed offering. Readers are cautioned that these forward-looking
statements are only predictions and may differ materially from actual future
events or results due to a variety of factors, including, among other things,
the demand for the Company’s products, the ability of the Company to produce
the products to meet the demand, global economic conditions and uncertainties
in the geopolitical environment and other risk factors set forth in the
Company’s most recent reports on Form 10-K and Form 10-Q. Any forward-looking
statements in this release are based on limited information currently
available to the Company, which is subject to change, and the Company will not
necessarily update the information

Contact:

BSD Medical Corporation
William Barth, 801-972-5555
fax: 801-972-5930
investor@bsdmc.com